Forum Merger II Corp. (FMCI), filed an 8-K this afternoon releasing the details of today’s shareholder vote to extend their deadline from February 7, 2020 to June 10, 2020, and once again, we had another extremely good vote.
As you can see below, FMCI had zero “No” votes and more importantly, only 4,589 out of 20,000,000 public shares were redeemed. No word on at what price those 4,589 shares were redeemed, but presumably we’ll get that in a later filing. However, as a result of the extension, the Company will make a cash contribution into its trust account of $0.033 for each public share that was not redeemed at today’s vote.
FMCI now has four more months to announce and close a deal….they’re on “combination watch” now, so let’s see what happens.
FOR | AGAINST | ABSTAIN | BROKER NON-VOTES |
19,876,961 | 0 | 0 | 0 |
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...